Sotera Health appoints Karen A. Flynn as new director, board expanded to 11

Sotera Health Co

Board increased from 10 to 11 members; Karen A. Flynn appointed effective Nov 13, 2023.
Flynn most recently served as Interim President of BioModalities at Catalent Pharma Solutions.
She is deemed independent under Nasdaq rules and will serve as Class II director until 2025 annual meeting.
She will receive standard non-employee director compensation (annual cash retainer + RSU grant).
No arrangements or transactions requiring disclosure; enters customary indemnification agreement.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Karen A. Flynn

director

SHC · Sotera Health Co

Effective: 2023-11-13
Filed: November 13, 2023, 6:59 PM ET

On November 13, 2023, the Board of Directors (the “Board”) of Sotera Health Company (the “Company”) increased the size of the Board from ten to eleven and appointed Karen A. Flynn to serve as a director of the Company effective November 13, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karen A. Flynn was appointed as director at Sotera Health Co.

Action: appointed
Role: director

Exact text from the filing

On November 13, 2023, the Board of Directors (the “Board”) of Sotera Health Company (the “Company”) increased the size of the Board from ten to eleven and appointed Karen A. Flynn to serve as a director of the Company effective November 13, 2023.

View on SEC.gov

Sotera Health Co filing history →

Source: SEC EDGAR

accession 0001822479-23-000065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.